Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | PRKCA | P17252 | 2/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716599 | 0.93 | LMNA (0.68) | LMNAL3MBTL1MAOBNR1H4ALDH1A1 | |
| SCHEMBL27900716 | 0.90 | LMNA (0.65) | LMNAL3MBTL1MAOBNR1H4ALDH1A1 | |
| SCHEMBL7401422 | 0.83 | LMNA (0.71) | LMNAL3MBTL1MAOBNR1H4ALDH1A1 | |
| SCHEMBL31579489 | 0.83 | LTA4H (0.60) | LMNAL3MBTL1MAOBALDH1A1ALOX5 | |
| SCHEMBL583575 | 0.82 | MMP8 (0.68) | — | |
| SCHEMBL27973452 | 0.82 | LMNA (0.65) | LMNAL3MBTL1MAOBNR1H4ALDH1A1 | |
| SCHEMBL27759836 | 0.82 | LMNA (0.55) | LMNAL3MBTL1NR1H4ALDH1A1 | |
| SCHEMBL27759813 | 0.82 | LMNA (0.55) | LMNAL3MBTL1NR1H4ALDH1A1 | |
| SCHEMBL8871420 | 0.81 | LMNA (0.64) | LMNAL3MBTL1MAOBNR1H4ALDH1A1 | |
| SCHEMBL28365013 | 0.81 | MMP8 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | LMNA 3993/4885L3MBTL1 3913/4885MAOB 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.